Fox Run Management L.L.C. Makes New $339,000 Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

Fox Run Management L.L.C. bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the fourth quarter, Holdings Channel reports. The institutional investor bought 2,161 shares of the company’s stock, valued at approximately $339,000.

Other hedge funds have also made changes to their positions in the company. State Street Corp raised its stake in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after acquiring an additional 119,936 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Krystal Biotech during the fourth quarter worth approximately $15,989,000. Franklin Resources Inc. raised its stake in shares of Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after purchasing an additional 62,178 shares during the last quarter. Braidwell LP lifted its holdings in shares of Krystal Biotech by 57.4% during the third quarter. Braidwell LP now owns 168,691 shares of the company’s stock worth $30,707,000 after purchasing an additional 61,512 shares during the period. Finally, TimesSquare Capital Management LLC grew its position in Krystal Biotech by 39.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company’s stock valued at $24,888,000 after buying an additional 44,646 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on KRYS shares. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. Chardan Capital increased their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Finally, Citigroup lifted their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $220.00.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $187.10 on Thursday. The stock has a fifty day moving average price of $169.36 and a 200 day moving average price of $173.77. The stock has a market cap of $5.39 billion, a PE ratio of 62.58 and a beta of 0.87. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business’s revenue was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.30 EPS. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).